Literature DB >> 14575303

Differential effects of calpain inhibitors on hypertrophy of cardiomyocytes.

Jay R Pollack1, Richard C Witt, Jeffrey T Sugimoto.   

Abstract

Two inhibitors of the calcium-dependent cysteine protease, calpain, have markedly different effects on the extent of hypertrophy induced by the alpha-adrenergic agonist, phenylephrine, of cultured neonatal rat ventricular myocytes. E64c, an inhibitor of calpain and other cysteine proteases, stimulated the hypertrophy by 59%. PD 150606, a specific calpain inhibitor, reduced the hypertrophy by 38%. Phenylephrine decreased the proteolysis of a calpain substrate by the cells 1-2 h after its addition but not at 24 h. PD 150606 inhibited proteolytic activity at all times, and the combination of phenylephrine and PD 150606 did not give greater inhibition. This suggests that cysteine proteases of the papain sub-family are involved with the hypertrophic response at two points, promoting hypertrophy at the first and limiting it at the second. Calpain appears to be the protease involved at the first point, and there may be another cysteine protease acting at the second site.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14575303

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  22 in total

1.  Stratum corneum thiol protease (SCTP): a novel cysteine protease of late epidermal differentiation.

Authors:  A Watkinson
Journal:  Arch Dermatol Res       Date:  1999-05       Impact factor: 3.017

2.  Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy.

Authors:  T Taigen; L J De Windt; H W Lim; J D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

3.  An alpha-mercaptoacrylic acid derivative is a selective nonpeptide cell-permeable calpain inhibitor and is neuroprotective.

Authors:  K K Wang; R Nath; A Posner; K J Raser; M Buroker-Kilgore; I Hajimohammadreza; W Probert A; F W Marcoux; Q Ye; E Takano; M Hatanaka; M Maki; H Caner; J L Collins; A Fergus; K S Lee; E A Lunney; S J Hays; P Yuen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

4.  MDL-28170, a membrane-permeant calpain inhibitor, attenuates stunning and PKC epsilon proteolysis in reperfused ferret hearts.

Authors:  F Urthaler; P E Wolkowicz; S B Digerness; K D Harris; A A Walker
Journal:  Cardiovasc Res       Date:  1997-07       Impact factor: 10.787

5.  Erythrocyte calpain activity and left ventricular mass in essential hypertension.

Authors:  P Stella; L Soldati; D Ciurlino; G Vezzoli; D Cusi; G Bianchi
Journal:  J Hypertens       Date:  1997-12       Impact factor: 4.844

6.  Chronic pressure overload cardiac hypertrophy and failure in guinea pigs: II. Cytoskeletal remodeling.

Authors:  X Wang; F Li; S E Campbell; A M Gerdes
Journal:  J Mol Cell Cardiol       Date:  1999-02       Impact factor: 5.000

7.  A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy.

Authors:  G D Arthur; A N Belcastro
Journal:  Mol Cell Biochem       Date:  1997-11       Impact factor: 3.396

8.  Maitotoxin induces calpain activation in SH-SY5Y neuroblastoma cells and cerebrocortical cultures.

Authors:  K K Wang; R Nath; K J Raser; I Hajimohammadreza
Journal:  Arch Biochem Biophys       Date:  1996-07-15       Impact factor: 4.013

9.  L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.

Authors:  A J Barrett; A A Kembhavi; M A Brown; H Kirschke; C G Knight; M Tamai; K Hanada
Journal:  Biochem J       Date:  1982-01-01       Impact factor: 3.857

10.  Distinct alpha 1-adrenergic agonist- and endothelin-1-evoked phosphoinositide cycle responses in cultured neonatal rat cardiomyocytes.

Authors:  H W de Jonge; H A van Heugten; K Bezstarosti; J M Lamers
Journal:  Biochem Biophys Res Commun       Date:  1994-08-30       Impact factor: 3.575

View more
  3 in total

1.  In vivo administration of calpeptin attenuates calpain activation and cardiomyocyte loss in pressure-overloaded feline myocardium.

Authors:  Santhosh K Mani; Hirokazu Shiraishi; Sundaravadivel Balasubramanian; Kentaro Yamane; Meenakshi Chellaiah; George Cooper; Naren Banik; Michael R Zile; Dhandapani Kuppuswamy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-05-16       Impact factor: 4.733

2.  Attenuation of cellular toxicity by calpain inhibitor induced by bacterial endotoxin: a mechanistic study using muscle precursor cells as a model system.

Authors:  Ke Shang; Junfeng Zhang; Touseef Amna; Jieun Yang; Xiangchao Cheng; Chunjie Zhang; Inho Hwang
Journal:  Mol Biol Rep       Date:  2015-03-27       Impact factor: 2.316

Review 3.  Calpains as Potential Therapeutic Targets for Myocardial Hypertrophy.

Authors:  David Aluja; Sara Delgado-Tomás; Marisol Ruiz-Meana; José A Barrabés; Javier Inserte
Journal:  Int J Mol Sci       Date:  2022-04-07       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.